Clinical observation on patients older than seventy years with AECOPD treated with budesonide in combination with salbutamol sulfate and ambroxol through fog inhalation
10.3760/cma.j.issn.1008-6315.2011.08.013
- VernacularTitle:布地奈德联合硫酸沙丁胺醇及氨溴索雾化吸入治疗70岁以上慢性阻塞性肺疾病急性加重期患者的临床观察
- Author:
Jue GU
;
Lingyun ZHANG
- Publication Type:Journal Article
- Keywords:
Acute exacerbation chronic obstructive pneumonia disease;
Budesonide;
Salbutamol sulfate;
Ambroxol
- From:
Clinical Medicine of China
2011;27(8):819-821
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical efficacy of budesonide in combination with salbutamol sulfate and ambroxol through fog inhalation in the treatment of elderly patients older than 70 years with acute exacerbation chronic obstructive pneumonia disease (AECOPD). Methods A total of 58 elderly patients older than 70 years with AECOPD were randomly assigned to receive medication of budesonide in combination with salbutamol sulfate and ambroxol through fog inhalation in addition to conventional therapy ( n = 58 treatment group). In the control group,56 AECOPD patients received conventional therapy (including oxygen uptaking,anti-infection, medication, relieving asthma, eliminating sputum, nutritional support, et al). Results The overall effective rate in the treatment group was 76.79% (43/56) ,which was significantly lower than that in the control group 89. 66% (52/58) ( χ2 = 6. 46, P = 0. 007 ). Blood gas analysis ( pH, PaCO2, PaO2 ) and lung function ( FEV1/FVC, FEV1 occupy prospect% ) outcome were significantly improved after treatment (Ps < 0.05 ). We found no significant difference in the comparison of the blood gas analysis improvement between the treatment and control ( Ps > 0. 05 ), whereas significant difference was observed in the improvement on lung function between the two groups (P < 0. 05 ). Conclusion Combined budesonide with salbutamol sulfate and ambroxol through fog inhalation in addition to conventional therapy has a significant better effect and less side effects on the treatment of AECOPD patients older than 70 years.